(Marketwire - July 18, 2008) - Leiden, The Netherlands, July 18, 2008. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) announced today its financial results for the first half year (HY1) of 2008 for the period ended June 30, 2008. In addition, the Company highlighted the positive results from randomized and ongoing open-label studies in Europe and North America, which allow it to move forward with regulatory filings for Rhucin® (recombinant human C1 inhibitor or rhC1INH) for the treatment of acute attacks of Hereditary Angioedema (HAE) in several markets.
